Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 46,485	$ 56,409
Prepaid expenses and other current assets	2,419	3,109
Total current assets	48,904	59,518
Operating lease asset, net	647	739
In-process research and development	32,386	32,386
Other assets	369	150
Total assets	82,306	92,793
Current liabilities:
Accounts payable	2,852	2,200
Current operating lease liabilities	384	363
Accrued expenses and other liabilities	2,242	3,912
Total current liabilities	5,478	6,475
Deferred tax liabilities	1,752	1,752
Non-current operating lease liabilities	284	383
Total liabilities	7,514	8,610
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2023 and December, 31, 2022; 13,776,788 shares issued and outstanding at March 31, 2023 and December 31, 2022	14	14
Additional paid-in capital	288,415	287,034
Accumulated deficit	(213,637)	(202,865)
Total stockholders’ equity	74,792	84,183
Total liabilities and stockholders’ equity	82,306	92,793
Series X1 Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Series X Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value

In-process research and development.

No definition available.

Name:	eldn_InProcessResearchAndDevelopment
Namespace Prefix:	eldn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).